Discount rate adjustment for the health of future generations

17 May 2022 - Medicines Australia has released a video detailing the need for Australia to adjust its discount rate ...

Read more →

Next Health Minister must restart the National Medicines Policy Review

10 May 2022 - Medicines Australia has released a video outlining the importance of restarting the National Medicines Policy Review ...

Read more →

What is the HTA review and why is it important for Australia’s health system?

3 May 2022 - Medicines Australia has released its fourth video in its Federal Election series, explaining the upcoming independent ...

Read more →

Health Technology Assessment Review Reference Committee will drive reform to support Australian patients

10 April 2022 - The Health Technology Assessment Review Reference Committee announced (via the Department of Health website) is tasked ...

Read more →

Life Saving Drugs Program – medicines reviews recommendations

7 April 2022 - This document outlines 51 recommendations from the Life Saving Drugs Expert Panel review. ...

Read more →

Consultation now open - review of base case discount rate at 3A.1 of the PBAC Guidelines

5 April 2022 - The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment ...

Read more →

DUSC utilisation analysis public release documents

25 March 2022 - The utilisation analysis public release documents from the October 2021 DUSC meeting are now available. ...

Read more →

Government opts for additional consultation on National Medicines Policy review

24 March 2022 - The Government has heeded the calls from Medicines Australia, patient groups, health bodies, and industry by ...

Read more →

National Medicines Policy too important to be rushed before Federal Election

10 February 2022 - Following consultation with members – and heeding the concerns of the Consumers Health Forum and patient ...

Read more →

Review of the National Medicines Policy – consultation on draft National Medicines Policy extended

8 February 2022 - The consultation period on the draft NMP was due to close on Wednesday 16 February 2022.  ...

Read more →

Medicines Australia calls for new National Medicines Policy to be pushed back until after the federal election

4 February 2022 - Medicines Australia is today calling for the new National Medicines Policy to be pushed back until ...

Read more →

Review of the National Medicines Policy – consultation on the draft closes 16 February 2022

2 February 2022 - Since August 2021, the Committee has heard from nearly 200 stakeholders through bilateral interviews and virtual group ...

Read more →

How are child specific utility instruments used in decision making in Australia? A review of Pharmaceutical Benefits Advisory Committee public summary documents.

28 January 2022 - Measuring and valuing health-related quality of life in children can be challenging but is an important component ...

Read more →

National Medicines Policy Review – publication of submissions

21 January 2022 - On 30 August 2021, the National Medicines Policy Review Committee invited submissions to support the Review of ...

Read more →

Preparing for health care’s new frontier: Committee releases major report on reforming the process for new medicines and health technology

25 November 2021 - A new parliamentary report ‘The New Frontier: Delivering better health for all Australians’ is recommending significant ...

Read more →